{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"14"}],"units":"Participants"}],"description":"Immune-related ORR is defined as the percentage of patients achieving a irCR or irPR based on irRECIST criteria. PD-L1 positivity was defined as Combined Positive Score ≥1. Evaluated objective response in PD-L1 positive patients\n\nPer irRECIST: Immune-related (ir) Complete Response (irCR), disappearance of all target and non-target lesions, nodal short axis diameter \\<10 mm, no new lesions; irPartial Response (irPR), decrease of ≥30% in tumor burden relative to baseline, non-unequivocal progression of non-target lesions, no new lesions.","groups":[{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG000","title":"Cohort 1: Squamous Cell Carcinoma of the Skin"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG001","title":"Cohort 2: Small Cell Malignancies of Nonpulmonary Origin"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG002","title":"Cohort 3: Adrenocortical Carcinoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG003","title":"Cohort 4: Medullary Renal Cell Carcinoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG004","title":"Cohort 5: Carcinoma of Unknown Primary"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG005","title":"Cohort 6: Penile Carcinoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG006","title":"Cohort 7: Vascular Sarcoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG007","title":"Cohort 8: Germ Cell Tumor"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG008","title":"Cohort 9: Paraganglioma-pheochromocytoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG009","title":"Cohort 10: Other Rare Tumor Histologies"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"PD-L1 expression on tumor and mononuclear inflammatory cells in tumor nests were assessed on samples obtained prior to treatment. Patients with PD-L1 positive disease (CPS ≥1) were evaluated for objective response.","reportingStatus":"POSTED","timeFrame":"Baseline and every 9 weeks thereafter. After 6 months, every 12 weeks at the physician's discretion, if patient has had CR, PR, or SD > 27 weeks, an average of 4 years.","title":"Evaluation of Tumor Size (Objective Response by irRECIST) to PD-L1 Status (CPS ≥1)","type":"SECONDARY","unitOfMeasure":"Participants"}